Lawson Kroeker Investment Management Inc. NE lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,640 shares of the medical research company’s stock after selling 305 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.3% of Lawson Kroeker Investment Management Inc. NE’s investment portfolio, making the stock its 28th biggest holding. Lawson Kroeker Investment Management Inc. NE’s holdings in Thermo Fisher Scientific were worth $3,919,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Bank of Nova Scotia Trust Co. acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at approximately $106,000. Ropes Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares during the period. Atlantic Trust LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $138,000. Acrospire Investment Management LLC increased its stake in shares of Thermo Fisher Scientific by 66.7% in the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 400 shares during the period. Finally, Glassman Wealth Services increased its stake in shares of Thermo Fisher Scientific by 23.1% in the second quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 195 shares during the period. Institutional investors own 86.25% of the company’s stock.

Several brokerages have commented on TMO. Barclays restated an “overweight” rating and issued a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price target on the stock in a research note on Thursday, September 21st. Jefferies Group restated a “hold” rating and issued a $195.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Leerink Swann restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Monday, October 30th. Finally, BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have assigned a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $212.21.

In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Inc. (TMO) traded down $2.16 during midday trading on Wednesday, hitting $208.01. 2,264,200 shares of the company were exchanged, compared to its average volume of 1,614,720. Thermo Fisher Scientific Inc. has a fifty-two week low of $140.00 and a fifty-two week high of $211.81. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $83,580.00, a price-to-earnings ratio of 35.32, a PEG ratio of 1.71 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same quarter last year, the business earned $2.03 earnings per share. The business’s revenue for the quarter was up 13.9% on a year-over-year basis. analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, January 15th. Investors of record on Friday, December 15th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

ILLEGAL ACTIVITY NOTICE: “Lawson Kroeker Investment Management Inc. NE Reduces Position in Thermo Fisher Scientific Inc. (TMO)” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/17/lawson-kroeker-investment-management-inc-ne-reduces-position-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.